Shopping News / Articles
Tech Funding News
techfundingnews. com > cellares-277m-series-d-ark-invest-cell-therapy

Cathie Wood's ARK Invest joins Cellares' $277 M round to help bring cell therapies to more patients " TFN

2+ hour, 5+ min ago  (624+ words) Cell therapy has long promised to transform medicine, offering personalised treatments capable of tackling cancer, autoimmune diseases, and other complex conditions." Yet despite the scientific breakthroughs, one challenge has consistently held the industry back: manufacturing. Unlike traditional drugs, cell therapies…...

Symbols: nasdaq:fate,btc-usd,nasdaq:fblg,nasdaq:meso,nasdaq:lgvn
Medical Daily
medicaldaily. com > virginia-measles-record-buckingham-county-outbreak-2026-475561

Virginia Records Most Measles Cases Ever as Buckingham County Outbreak Continues

4+ hour, 34+ min ago  (729+ words) How to Live Better, Longer Virginia is experiencing the worst measles year in its recorded history. As of June 2, 2026, the Virginia Department of Health (VDH) has confirmed 77 measles cases statewide " a figure that surpasses any previous annual total for the…...

@Europ Hospital
healthcare-in-europe. com

Pharma's Competitive Advantage at AUTOMA+ 2026

24+ min ago  (178+ words) Image source: BGS Group Despite these examples, a key obstacle remains: the gap between executive ambition and operational reality. Bridging this divide requires a performance management framework that translates strategic goals into shopfloor actions, as well as a clear understanding…...

Symbols: btc-usd
newztodays
newztodays. com > islamabad-inaugurates-new-school-of-pharmaceutical-sciences

Islamabad Inaugurates New School of Pharmaceutical Sciences

28+ min ago  (154+ words) The Federal Minister for National Health Services, Regulations and Coordination, Syed Mustafa Kamal, officially inaugurated the School of Pharmaceutical Sciences at the Health Services Academy (HSA), Islamabad. This development marks a significant step in enhancing pharmaceutical education, research in public…...

Lincoln Journal
lincolnjournal. com > online_features > press_releases > sensorion-achieves-key-regulatory-milestones-for-sens-601-for-gjb2-related-hearing-loss-and-selects > article_62347f23-1817-5f77-96f9-f7c9bbbdcdfe. html

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

2+ hour, 57+ min ago  (171+ words) lincolnjournal. com Click #isupportlocal for more information on supporting our local journalists. Sensorion (FR0012596468 " ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the selection of SENS…...

Symbols: otof-gt
Labiotech. eu
labiotech. eu > in-depth > neurology-technology

Beyond amyloid and dopamine: emerging technologies reshaping neurology

30+ min ago  (563+ words) However, the progresshas been limited. Some genes are too large for conventional gene therapy vectors. Many therapies struggle to reach the brain in sufficient quantities. But our understanding of these conditions has also improved. Blood-brain barrier (BBB) dysfunction and neuroinflammation…...

Symbols: nasdaq:abos
The Hearty Soul
theheartysoul. com > one-time-cholesterol-drug

Scientists Working on One-Time Drug to Permanently Fix High Cholesterol. It's Actually Working

42+ min ago  (586+ words) The drug is called CTX310. It doesn't add anything to the body, and it doesn't need to be taken daily. It goes in once, finds its target in the liver, and the gene it silences stays silent. Understanding how it does…...

Euractiv
euractiv. com > news > first-aid-patents-or-patients

FIRST AID: Patents or patients?

1+ hour, 39+ min ago  (12+ words) Euractiv In today's edition: drugs, HTA, EUCO...

NZ Doctor
nzdoctor. co. nz > media > 25103

(Ministry of Health) Fast-track improvements to medicines regulation under the Medical Products Bill

1+ hour, 19+ min ago  (268+ words) NZ Doctor Website intended for a New Zealand health professional readership (Ministry of Health) Fast-track improvements to medicines regulation under the Medical Products Bill In last month's article, "Explaining chronic pain, specialist pain medicine physician John Alchin outlined the different…...

The Manila Times
manilatimes. net > 06/10/2026 > tmt-newswire > globenewswire > connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome > 2362396

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

35+ min ago  (74+ words) The study has been authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS), with approvals from the relevant ethics committees, and is funded by the Spanish Ministry of Science, Innovation and Universities and the European Union's Next Generation…...

Symbols: nasdaq:dsgn
Shopping

Please enter a search for detailed shopping results.